Pitfalls of hormonal injection therapy in prostate cancer

International Journal of Clinical Practice

Volumn 63, Issue 5, 2009, Pages 820-822

  Koo, V ^a   Young, M ^a   O'Brien, A ^a  

^a CRAIGAVON AREA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ANAMNESIS; ANXIETY; ARTICLE; CANCER HORMONE THERAPY; CASE REPORT; CLINICAL FEATURE; HUMAN; MALE; PATIENT COMPLIANCE; PATIENT REFERRAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; TESTOSTERONE BLOOD LEVEL; TREATMENT REFUSAL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, LHRH; RETROSPECTIVE STUDIES; TESTOSTERONE;

EID: 64149093473     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01978.x     Document Type: Article

References (4)

1. Cancer Research UK. Cancer Stats: Incidence - UK, 2008. http://info.cancerresearchuk.org (accessed July 2008).
2. Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2008 53 : 68 80.
3. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000 164 : 726 9.
4. Pathak AS, Pacificar JS, Shapiro CE, Williams SG. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. J Urol 2007 177 : 2132 5.